New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis a vaccine 50 u/ml - suspension for injection - 50 u/ml - active: hepatitis a vaccine 50 u/ml excipient: aluminium as amorphous aluminium hydroxyphosphate sulphate borax sodium chloride water for injection - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus. primary immunisation should be given at least 2 weeks prior to expected exposure to hav. vaccination is recommended in children 12 months of age and older, adolescents, and adults who are at risk of contracting or spreading infection or who are at risk of life-threatening disease if infected, including but not limited to: · travellers to endemic or outbreak areas · frequently affected communities - members residing in any community with one or more recorded outbreaks within the last five years · daycare - children and staff of daycare centres as well as their parents, siblings, and other contacts · military personnel prior to departure for endemic or outbreak areas · persons for whom hepatitis a is an occupational hazard - health-care workers - staff and residents of orphanages, chronic care hospitals and mental health care facilities - sewage workers · haemophiliacs and other recipients of therapeutic blood products · persons who test positive for hepatitis c virus and have diagnosed liver disease · food handlers · consumers of high-risk foods e.g. raw shellfish · persons at increased risk of the disease due to their sexual practices - homosexually-active males - persons who repeatedly contract sexually transmitted diseases · human immunodeficiency virus (hiv)-infected adults · users of illicit injectable drugs vaqta will not prevent hepatitis caused by infectious agents other than hepatitis a virus.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 10 µg/ml - suspension for injection - 10 mcg/ml - active: hepatitis b vaccine, rdna 10 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 40 µg/ml - suspension for injection - 40 mcg/ml - active: hepatitis b vaccine, rdna 40 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 250mg equivalent to 200 mg indinavir;  ;   - capsule - 200 mg - active: indinavir sulfate 250mg equivalent to 200 mg indinavir     excipient: gelatin lactose magnesium stearate tekprint blue sb-6018 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 416.3mg equivalent to 333 mg indinavir;  ;   - capsule - 333 mg - active: indinavir sulfate 416.3mg equivalent to 333 mg indinavir     excipient: gelatin lactose magnesium stearate

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 500mg equivalent to 400 mg indinavir;  ;   - capsule - 400 mg - active: indinavir sulfate 500mg equivalent to 400 mg indinavir     excipient: gelatin lactose magnesium stearate tekprint green sb-4020 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage).; imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).;   - powder for infusion - 500mg/500mg - active: cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage). imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).   excipient: sodium bicarbonate

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - rotavirus reassortant strain g1 2.2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g2 2.8e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g3 2.2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g4 2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain p1 2.3e+006 [iu] (nlt, at expiry) - oral solution - 2 ml - active: rotavirus reassortant strain g1 2.2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g2 2.8e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g3 2.2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g4 2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain p1 2.3e+006 [iu] (nlt, at expiry) excipient: rotavirus diluent & lpkm-3 (from actives) to approx 0.3 ml. includes animal materials as below. monobasic sodium phosphate monohydrate polysorbate 80 purified water sodium citrate dihydrate sodium hydroxide sucrose - rotateq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, g4, and g-serotypes that contain p1a[8] (e.g., g9). rotateq may be administered as early as six weeks of age.